---
id: 207
title: Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP)
category: clinical_syndromes
subcategory: respiratory
tags: [HAP, VAP, nosocomial-pneumonia, MRSA, Pseudomonas, ventilator]
difficulty: high
---

## Question

How are HAP/VAP managed? Use **"Cover MRSA (Vanc/Linezolid) + Pseudomonas (Pip-Tazo/Cefepime/Carbapenem) × 7d, De-escalate by Day 3"** framework.

## Answer

### **Definitions:**

**Hospital-Acquired Pneumonia (HAP):**
- **Pneumonia ≥48h after hospital admission** (NOT incubating at admission)

**Ventilator-Associated Pneumonia (VAP):**
- **Pneumonia ≥48h after endotracheal intubation**

### **Diagnosis:**

**Clinical:**
- **New infiltrate on CXR** + **≥2 of:**
  - Fever (>38°C) or hypothermia (<36°C)
  - Leukocytosis (>12,000) or leukopenia (<4,000)
  - Purulent sputum
  - Worsening oxygenation

**Microbiologic:**
- **Sputum culture** (if good quality: <10 squamous epithelial cells, >25 PMNs per LPF)
- **Endotracheal aspirate** (quantitative: ≥10⁶ CFU/mL)
- **Bronchoalveolar lavage (BAL):** ≥10⁴ CFU/mL (gold standard, but invasive)
- **Blood cultures** (positive in 10-25%)

### **Microbiology:**

**Common Pathogens:**
- ***Pseudomonas aeruginosa*** (15-25%)
- ***Staphylococcus aureus*** (MSSA/MRSA) (20-30%)
- ***Klebsiella pneumoniae*, *E. coli*, *Enterobacter*, *Acinetobacter***
- ***Stenotrophomonas maltophilia***

**Risk Factors for MDROs:**
- **≥5 days hospitalization**
- **Recent antibiotics** (within 90 days)
- **Septic shock**
- **ARDS requiring mechanical ventilation**
- **Renal replacement therapy** (hemodialysis)
- **Local MDR prevalence >25%**

### **Empiric Treatment:**

**Standard HAP/VAP (Cover MRSA + Pseudomonas):**

**MRSA Coverage (Choose ONE):**
- **Vancomycin 15-20 mg/kg IV q8-12h** (target trough 15-20 mcg/mL for serious infections)
- **Linezolid 600mg IV/PO BID** (if MRSA MIC >1.5 for vancomycin, or lung penetration concern)

**Pseudomonas/Gram-Negative Coverage (Choose ONE):**
- **Piperacillin-tazobactam 4.5g IV q6h** (extended infusion preferred)
- **Cefepime 2g IV q8h**
- **Meropenem 1g IV q8h** OR **imipenem 500mg IV q6h** (if high local resistance or prior MDROs)
- **Aztreonam 2g IV q8h** (if β-lactam allergy, but does NOT cover Gram-positives)

**Double Pseudomonas Coverage (If High Risk for MDR *Pseudomonas*):**
- **β-lactam** (above) + **aminoglycoside** (gentamicin 7 mg/kg IV daily or amikacin 20 mg/kg IV daily) OR **fluoroquinolone** (ciprofloxacin 400mg IV q8h, levofloxacin 750mg IV daily)
- **Indications:** Septic shock, prior MDR *Pseudomonas*, high local resistance

**Duration:**
- **7 days** (if clinical improvement)
- **Extend to 14 days** if: *Pseudomonas*, *Acinetobacter*, MRSA with slow response, lung abscess/empyema

### **De-escalation (Day 3):**

**Key Principle:**
- **Narrow based on cultures** (stop MRSA coverage if no MRSA, switch to narrow-spectrum β-lactam if susceptible)
- **Reassess need for antibiotics** (if cultures negative + clinical improvement, consider stopping)

**Procalcitonin-Guided:**
- **PCT <0.5 ng/mL** or **≥80% drop** from peak → consider stopping antibiotics

### **Special Situations:**

***Legionella* (Consider If):**
- **Severe CAP progressing to HAP**, **travel/water exposure**, **hyponatremia**
- **Add:** Azithromycin 500mg IV daily OR levofloxacin 750mg IV daily (covers atypical + Gram-negatives)

***Aspergillus* (Immunocompromised):**
- **Prolonged neutropenia, transplant, high-dose steroids**
- **Voriconazole 6 mg/kg IV q12h × 2, then 4 mg/kg IV q12h**

***Stenotrophomonas maltophilia*:**
- **TMP-SMX 5 mg/kg (TMP component) IV q8h**
- **Often resistant** to carbapenems

**MDR *Acinetobacter baumannii*:**
- **Carbapenem-resistant:** Colistin (polymyxin E) 5 mg/kg loading, then 2.5 mg/kg IV q12h OR cefiderocol 2g IV q8h (over 3h infusion)

### **Prevention:**

**VAP Bundle:**
- **Head of bed elevation** (30-45°)
- **Oral care** (chlorhexidine)
- **Sedation vacation, spontaneous breathing trials** (minimize ventilator days)
- **Subglottic suctioning** (ETT with suction port above cuff)
- **Avoid unnecessary proton pump inhibitors** (↑aspiration risk)

### **Prognosis:**

**Mortality:**
- **HAP:** 15-30%
- **VAP:** 20-50% (higher if MDR pathogens, *Pseudomonas*, *Acinetobacter*)

## Key Points

### **Empiric = MRSA Coverage + Pseudomonas Coverage:**
- **Vancomycin** (or linezolid) + **pip-tazo** (or cefepime, meropenem)
- **Double cover *Pseudomonas*** if septic shock, prior MDR

### **7 Days Duration:**
- **Adequate** for most HAP/VAP if clinical improvement
- **14 days** if *Pseudomonas*, *Acinetobacter*, slow response

### **De-escalate by Day 3:**
- **Narrow based on cultures**
- **Stop MRSA coverage** if no MRSA
- **Switch to narrow-spectrum** if susceptible

### **PCT-Guided Discontinuation:**
- **PCT <0.5 ng/mL** or **≥80% drop** → consider stopping
- **Reduces antibiotic duration** without increasing mortality

### **VAP Prevention:**
- **Head of bed ↑, oral care, minimize ventilator days** (sedation vacations, SBTs)

### **Clinical Pearls:**
- **HAP/VAP:** Vancomycin + pip-tazo (or cefepime/meropenem) × 7 days
- **De-escalate by day 3** based on cultures
- **Double cover *Pseudomonas*** if septic shock, prior MDR
- **Duration 7 days** (adequate if improving), 14 days (if *Pseudomonas*, slow response)
- **VAP prevention:** HOB ↑, oral care, minimize vent days

## Sources

- [IDSA/ATS: Hospital-Acquired Pneumonia Guidelines 2024]
- [CID: VAP Management 2024]

## Media

N/A
